What question did this study set out to answer?

To assess neurologic outcomes in patients with Lambert Eaton Myasthenic Syndrome treated with immune checkpoint inhibitors.

November 1, 2025Neuro-OncologyOpen Access

NCMP-38. To Treat or Not To Treat - Immune Checkpoint Inhibition in Patients with SCLC-associated LEMS

View Full Paper

Ask AI

Bookmark

Authors

Case series reveals neurologic outcomes in patients with LEMS and SCLC, suggesting caution with immunotherapy.

To assess neurologic outcomes in patients with Lambert Eaton Myasthenic Syndrome treated with immune checkpoint inhibitors.
Case series involving two patients with SCLC-associated LEMS
Assessment of treatment with ICI, carboplatin, etoposide, and supportive therapies
Neurological evaluations pre- and post-treatment
One patient improved neurologically after initiating amifampridine and ICI treatment
Both patients had LEMS symptoms exacerbated by ICI
One patient achieved cancer remission with SCLC, while ICI was discontinued due to worsening LEMS symptoms

Primdahl et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark